Biohaven Ltd.
Last updated September 27, 2026
Organization details
- Legal name
- Biohaven Ltd.
- Former names
- Biohaven Research Ltd.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Virgin Islands, British
- Headquarters city
- New Haven
- Headquarters state / province
- Connecticut
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BHVN
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001935979
Board of directors
-
Gregory Bailey · DirectorSince 2023
-
Irina Antonijevic · DirectorSince 2023
-
John W. Childs · DirectorSince 2023
-
John Yetimoglu · DirectorSince 2026
-
Julia P. Gregory · DirectorSince 2023
-
Kishan Mehta · DirectorSince 2023
- Since 2023
-
Robert J. Hugin · DirectorSince 2023
-
Vlad Coric · Director · Chief Executive OfficerSince 2023
Chief executives
Vlad Coric
· Chief Executive Officer
Dates unknown
Board connections
7 of this board's directors also sit on 10 other boards.
- via John W. Childs and Vlad Coric
- via Michael Thomas Heffernan
- via Kishan Mehta
- via Robert J. Hugin
- via Michael Thomas Heffernan
- via Julia P. Gregory
- via Vlad Coric
- via Gregory Bailey
- via Michael Thomas Heffernan
- via Michael Thomas Heffernan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $33,144,833
- 5 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Kishan Mehta Director | Gift | −17,342 | — | — |
| Mar 17, 2026 | Kishan Mehta Director | Gift | +17,342 | — | — |
| Jan 5, 2026 | Gentile Kimberly Officer (SVP, Clinical Operations) | Option exercise | +3,750 | — | — |
| Jan 5, 2026 | Buten Matthew Officer (Chief Financial Officer) | Option exercise | +4,250 | — | — |
| Jan 5, 2026 | Vlad Coric Director, Officer (Chief Executive Officer) | Option exercise | +14,250 | — | — |
| Jan 5, 2026 | Car Bruce Officer (Chief Scientific Officer) | Option exercise | +4,750 | — | — |
| Jan 5, 2026 | Clark George C. Officer (VP, Chief Accounting Officer) | Option exercise | +2,500 | — | — |
| Jan 5, 2026 | Gentile Kimberly Officer (SVP, Clinical Operations) | Shares withheld for tax | −1,956 | $9.93 | $19,423 |
| Jan 5, 2026 | Buten Matthew Officer (Chief Financial Officer) | Shares withheld for tax | −2,594 | $9.93 | $25,758 |
| Jan 5, 2026 | Vlad Coric Director, Officer (Chief Executive Officer) | Shares withheld for tax | −7,430 | $9.93 | $73,780 |
| Jan 5, 2026 | Car Bruce Officer (Chief Scientific Officer) | Shares withheld for tax | −2,381 | $9.93 | $23,643 |
| Jan 5, 2026 | Clark George C. Officer (VP, Chief Accounting Officer) | Shares withheld for tax | −1,117 | $9.93 | $11,092 |
| Nov 17, 2025 | Clark George C. Officer (VP, Chief Accounting Officer) | Open-market purchase | +17,000 | $8.52 | $144,840 |
| Nov 13, 2025 | Gregory Bailey Director | Open-market purchase | +400,000 | $7.50 | $3,000,000 |
| Nov 13, 2025 | John W. Childs Director | Open-market purchase | +3,333,333 | $7.50 | $24,999,998 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.